APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cancer Immunotherapy Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Cancer Immunotherapy Drugs Industry Growth and Trends Forecast to 2032

Report ID 17397430012 January 2026129 pages

Choose your research edition.

Industry ResearchCancer Immunotherapy Drugs Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Immunotherapy Drugs Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Cancer Immunotherapy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Immunotherapy Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Immunotherapy Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Cancer Immunotherapy Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Cancer Immunotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Cancer Immunotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Immunotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Immunotherapy Drugs include Takeda, Johnson & Johnson, Novartis, Merck KGaA, Roche, Eli Lilly, Pfizer, GSK and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Cancer Immunotherapy Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Cancer Immunotherapy Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cancer Immunotherapy Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cancer Immunotherapy Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Cancer Immunotherapy Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Cancer Immunotherapy Drugs Market by Company

Takeda

Johnson & Johnson

Novartis

Merck KGaA

Roche

Eli Lilly

Pfizer

GSK

Amgen

AbbVie

AstraZeneca

Seagen

Regeneron

Ono Pharmaceutical

Merck & Co

Innovent

Hengrui Medicine

Gilead Sciences

Exelixis

Bristol-Myers Squibb

Cancer Immunotherapy Drugs Segment by Type

CAR-T Cell Therapy

Cytokine-Based Immunotherapy

Immune Checkpoint Inhibitors

Other

Cancer Immunotherapy Drugs Segment by Application

Blood-related Cancer

Breast Cancer

Prostate Cancer

Lung Cancer

Other

Cancer Immunotherapy Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Immunotherapy Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Cancer Immunotherapy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of CAR-T Cell Therapy Table 2. Major Company of Cytokine-Based Immunotherapy Table 3. Major Company of Immune Checkpoint Inhibitors Table 4. Major Company of Other Table 5. Global Cancer Immunotherapy Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 7. Global Cancer Immunotherapy Drugs Sales Market Share in Volume by Type (2021-2026) Table 8. Global Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (US$ Million) Table 9. Global Cancer Immunotherapy Drugs Sales Market Share in Value by Type (2021-2026) Table 10. Global Cancer Immunotherapy Drugs Price by Type (2021-2026) & (US$/Unit) Table 11. Global Cancer Immunotherapy Drugs Sales by Type (2027-2032) & (K Units) Table 12. Global Cancer Immunotherapy Drugs Sales Market Share in Volume by Type (2027-2032) Table 13. Global Cancer Immunotherapy Drugs Sales by Type (2027-2032) & (US$ Million) Table 14. Global Cancer Immunotherapy Drugs Sales Market Share in Value by Type (2027-2032) Table 15. Global Cancer Immunotherapy Drugs Price by Type (2027-2032) & (US$/Unit) Table 16. North America Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 17. North America Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 19. Europe Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 23. Latin America Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (US$ Million) Table 26. Cancer Immunotherapy Drugs Industry Trends Table 27. Cancer Immunotherapy Drugs Industry Drivers Table 28. Cancer Immunotherapy Drugs Industry Opportunities and Challenges Table 29. Cancer Immunotherapy Drugs Industry Restraints Table 30. Global Cancer Immunotherapy Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Cancer Immunotherapy Drugs Revenue Market Share by Company (2021-2026) Table 32. Global Cancer Immunotherapy Drugs Sales by Company (2021-2026) & (K Units) Table 33. Global Cancer Immunotherapy Drugs Sales Share by Company (2021-2026) Table 34. Global Cancer Immunotherapy Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Cancer Immunotherapy Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Cancer Immunotherapy Drugs Major Company Production Sites and Headquarters Table 37. Global Cancer Immunotherapy Drugs Company, Product Type & Application Table 38. Global Cancer Immunotherapy Drugs Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Cancer Immunotherapy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Cancer Immunotherapy Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Cancer Immunotherapy Drugs Sales by Region (2021-2026) & (K Units) Table 43. Global Cancer Immunotherapy Drugs Sales Market Share in Volume by Region (2021-2026) Table 44. Global Cancer Immunotherapy Drugs Sales by Region (2021-2026) & (US$ Million) Table 45. Global Cancer Immunotherapy Drugs Sales Market Share in Value by Region (2021-2026) Table 46. Global Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Cancer Immunotherapy Drugs Sales by Region (2027-2032) & (K Units) Table 48. Global Cancer Immunotherapy Drugs Sales Market Share in Volume by Region (2027-2032) Table 49. Global Cancer Immunotherapy Drugs Sales by Region (2027-2032) & (US$ Million) Table 50. Global Cancer Immunotherapy Drugs Sales Market Share in Value by Region (2027-2032) Table 51. Global Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Cancer Immunotherapy Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 54. Global Cancer Immunotherapy Drugs Sales Market Share in Volume by Application (2021-2026) Table 55. Global Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (US$ Million) Table 56. Global Cancer Immunotherapy Drugs Sales Market Share in Value by Application (2021-2026) Table 57. Global Cancer Immunotherapy Drugs Price by Application (2021-2026) & (US$/Unit) Table 58. Global Cancer Immunotherapy Drugs Sales by Application (2027-2032) & (K Units) Table 59. Global Cancer Immunotherapy Drugs Sales Market Share in Volume by Application (2027-2032) Table 60. Global Cancer Immunotherapy Drugs Sales by Application (2027-2032) & (US$ Million) Table 61. Global Cancer Immunotherapy Drugs Sales Market Share in Value by Application (2027-2032) Table 62. Global Cancer Immunotherapy Drugs Price by Application (2027-2032) & (US$/Unit) Table 63. North America Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 64. North America Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 66. Europe Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 70. Latin America Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (US$ Million) Table 73. Takeda Company Information Table 74. Takeda Business Overview Table 75. Takeda Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Takeda Cancer Immunotherapy Drugs Product Portfolio Table 77. Takeda Recent Development Table 78. Johnson & Johnson Company Information Table 79. Johnson & Johnson Business Overview Table 80. Johnson & Johnson Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Johnson & Johnson Cancer Immunotherapy Drugs Product Portfolio Table 82. Johnson & Johnson Recent Development Table 83. Novartis Company Information Table 84. Novartis Business Overview Table 85. Novartis Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Novartis Cancer Immunotherapy Drugs Product Portfolio Table 87. Novartis Recent Development Table 88. Merck KGaA Company Information Table 89. Merck KGaA Business Overview Table 90. Merck KGaA Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Merck KGaA Cancer Immunotherapy Drugs Product Portfolio Table 92. Merck KGaA Recent Development Table 93. Roche Company Information Table 94. Roche Business Overview Table 95. Roche Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Roche Cancer Immunotherapy Drugs Product Portfolio Table 97. Roche Recent Development Table 98. Eli Lilly Company Information Table 99. Eli Lilly Business Overview Table 100. Eli Lilly Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Eli Lilly Cancer Immunotherapy Drugs Product Portfolio Table 102. Eli Lilly Recent Development Table 103. Pfizer Company Information Table 104. Pfizer Business Overview Table 105. Pfizer Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Pfizer Cancer Immunotherapy Drugs Product Portfolio Table 107. Pfizer Recent Development Table 108. GSK Company Information Table 109. GSK Business Overview Table 110. GSK Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. GSK Cancer Immunotherapy Drugs Product Portfolio Table 112. GSK Recent Development Table 113. Amgen Company Information Table 114. Amgen Business Overview Table 115. Amgen Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Amgen Cancer Immunotherapy Drugs Product Portfolio Table 117. Amgen Recent Development Table 118. AbbVie Company Information Table 119. AbbVie Business Overview Table 120. AbbVie Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. AbbVie Cancer Immunotherapy Drugs Product Portfolio Table 122. AbbVie Recent Development Table 123. AstraZeneca Company Information Table 124. AstraZeneca Business Overview Table 125. AstraZeneca Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. AstraZeneca Cancer Immunotherapy Drugs Product Portfolio Table 127. AstraZeneca Recent Development Table 128. Seagen Company Information Table 129. Seagen Business Overview Table 130. Seagen Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Seagen Cancer Immunotherapy Drugs Product Portfolio Table 132. Seagen Recent Development Table 133. Regeneron Company Information Table 134. Regeneron Business Overview Table 135. Regeneron Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Regeneron Cancer Immunotherapy Drugs Product Portfolio Table 137. Regeneron Recent Development Table 138. Ono Pharmaceutical Company Information Table 139. Ono Pharmaceutical Business Overview Table 140. Ono Pharmaceutical Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Ono Pharmaceutical Cancer Immunotherapy Drugs Product Portfolio Table 142. Ono Pharmaceutical Recent Development Table 143. Merck & Co Company Information Table 144. Merck & Co Business Overview Table 145. Merck & Co Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Merck & Co Cancer Immunotherapy Drugs Product Portfolio Table 147. Merck & Co Recent Development Table 148. Innovent Company Information Table 149. Innovent Business Overview Table 150. Innovent Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Innovent Cancer Immunotherapy Drugs Product Portfolio Table 152. Innovent Recent Development Table 153. Hengrui Medicine Company Information Table 154. Hengrui Medicine Business Overview Table 155. Hengrui Medicine Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Hengrui Medicine Cancer Immunotherapy Drugs Product Portfolio Table 157. Hengrui Medicine Recent Development Table 158. Gilead Sciences Company Information Table 159. Gilead Sciences Business Overview Table 160. Gilead Sciences Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Gilead Sciences Cancer Immunotherapy Drugs Product Portfolio Table 162. Gilead Sciences Recent Development Table 163. Exelixis Company Information Table 164. Exelixis Business Overview Table 165. Exelixis Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Exelixis Cancer Immunotherapy Drugs Product Portfolio Table 167. Exelixis Recent Development Table 168. Bristol-Myers Squibb Company Information Table 169. Bristol-Myers Squibb Business Overview Table 170. Bristol-Myers Squibb Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 171. Bristol-Myers Squibb Cancer Immunotherapy Drugs Product Portfolio Table 172. Bristol-Myers Squibb Recent Development Table 173. North America Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 174. North America Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 175. North America Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2026) Table 176. North America Cancer Immunotherapy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 177. North America Cancer Immunotherapy Drugs Sales Market Share Forecast by Country (2027-2032) Table 178. North America Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. North America Cancer Immunotherapy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 180. North America Cancer Immunotherapy Drugs Market Share by Country (2021-2026) Table 181. North America Cancer Immunotherapy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. North America Cancer Immunotherapy Drugs Market Share Forecast by Country (2027-2032) Table 183. Europe Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 184. Europe Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 185. Europe Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2026) Table 186. Europe Cancer Immunotherapy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 187. Europe Cancer Immunotherapy Drugs Sales Market Share Forecast by Country (2027-2032) Table 188. Europe Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. Europe Cancer Immunotherapy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 190. Europe Cancer Immunotherapy Drugs Market Share by Country (2021-2026) Table 191. Europe Cancer Immunotherapy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. Europe Cancer Immunotherapy Drugs Market Share Forecast by Country (2027-2032) Table 193. Asia-Pacific Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 194. Asia-Pacific Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 195. Asia-Pacific Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2026) Table 196. Asia-Pacific Cancer Immunotherapy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 197. Asia-Pacific Cancer Immunotherapy Drugs Sales Market Share Forecast by Country (2027-2032) Table 198. Asia-Pacific Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 199. Asia-Pacific Cancer Immunotherapy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 200. Asia-Pacific Cancer Immunotherapy Drugs Market Share by Country (2021-2026) Table 201. Asia-Pacific Cancer Immunotherapy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 202. Asia-Pacific Cancer Immunotherapy Drugs Market Share Forecast by Country (2027-2032) Table 203. Latin America Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 204. Latin America Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 205. Latin America Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2026) Table 206. Latin America Cancer Immunotherapy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 207. Latin America Cancer Immunotherapy Drugs Sales Market Share Forecast by Country (2027-2032) Table 208. Latin America Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 209. Latin America Cancer Immunotherapy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 210. Latin America Cancer Immunotherapy Drugs Market Share by Country (2021-2026) Table 211. Latin America Cancer Immunotherapy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 212. Latin America Cancer Immunotherapy Drugs Market Share Forecast by Country (2027-2032) Table 213. Middle East and Africa Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 214. Middle East and Africa Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 215. Middle East and Africa Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2026) Table 216. Middle East and Africa Cancer Immunotherapy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 217. Middle East and Africa Cancer Immunotherapy Drugs Sales Market Share Forecast by Country (2027-2032) Table 218. Middle East and Africa Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 219. Middle East and Africa Cancer Immunotherapy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 220. Middle East and Africa Cancer Immunotherapy Drugs Market Share by Country (2021-2026) Table 221. Middle East and Africa Cancer Immunotherapy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 222. Middle East and Africa Cancer Immunotherapy Drugs Market Share Forecast by Country (2027-2032) Table 223. Key Raw Materials Table 224. Raw Materials Key Suppliers Table 225. Cancer Immunotherapy Drugs Distributors List Table 226. Cancer Immunotherapy Drugs Customers List Table 227. Research Programs/Design for This Report Table 228. Authors List of This Report Table 229. Secondary Sources Table 230. Primary Sources List of Figures Figure 1. Cancer Immunotherapy Drugs Image Figure 2. Global Cancer Immunotherapy Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Immunotherapy Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Immunotherapy Drugs Sales (2021-2032) & (K Units) Figure 5. CAR-T Cell Therapy Image Figure 6. Global CAR-T Cell Therapy Sales YoY Growth (2021-2032) & (K Units) Figure 7. Cytokine-Based Immunotherapy Image Figure 8. Global Cytokine-Based Immunotherapy Sales YoY Growth (2021-2032) & (K Units) Figure 9. Immune Checkpoint Inhibitors Image Figure 10. Global Immune Checkpoint Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 11. Other Image Figure 12. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Cancer Immunotherapy Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Cancer Immunotherapy Drugs Market Share by Type 2025 VS 2032 Figure 15. North America Cancer Immunotherapy Drugs Sales Market Share in Volume by Type in 2025 Figure 16. North America Cancer Immunotherapy Drugs Sales Market Share in Value by Type in 2025 Figure 17. Europe Cancer Immunotherapy Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Europe Cancer Immunotherapy Drugs Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Cancer Immunotherapy Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Cancer Immunotherapy Drugs Sales Market Share in Value by Type in 2025 Figure 21. Latin America Cancer Immunotherapy Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Cancer Immunotherapy Drugs Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Cancer Immunotherapy Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Cancer Immunotherapy Drugs Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Cancer Immunotherapy Drugs Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Blood-related Cancer Image Figure 28. Global Blood-related Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 29. Breast Cancer Image Figure 30. Global Breast Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 31. Prostate Cancer Image Figure 32. Global Prostate Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 33. Lung Cancer Image Figure 34. Global Lung Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 35. Other Image Figure 36. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 37. Global Cancer Immunotherapy Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Cancer Immunotherapy Drugs Market Share by Application 2025 VS 2032 Figure 39. North America Cancer Immunotherapy Drugs Sales Market Share in Volume by Application in 2025 Figure 40. North America Cancer Immunotherapy Drugs Sales Market Share in Value by Application in 2025 Figure 41. Europe Cancer Immunotherapy Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Europe Cancer Immunotherapy Drugs Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Cancer Immunotherapy Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Cancer Immunotherapy Drugs Sales Market Share in Value by Application in 2025 Figure 45. Latin America Cancer Immunotherapy Drugs Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Cancer Immunotherapy Drugs Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Cancer Immunotherapy Drugs Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Cancer Immunotherapy Drugs Sales Market Share in Value by Application in 2025 Figure 49. North America Cancer Immunotherapy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. North America Cancer Immunotherapy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Cancer Immunotherapy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Cancer Immunotherapy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Europe Cancer Immunotherapy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Cancer Immunotherapy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Cancer Immunotherapy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Asia-Pacific Cancer Immunotherapy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Cancer Immunotherapy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Cancer Immunotherapy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Latin America Cancer Immunotherapy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Cancer Immunotherapy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Cancer Immunotherapy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Middle East and Africa Cancer Immunotherapy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Cancer Immunotherapy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Cancer Immunotherapy Drugs Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Cancer Immunotherapy Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • CAR-T Cell Therapy
  • Cytokine-Based Immunotherapy
  • Immune Checkpoint Inhibitors
  • Other
Applications
  • Blood-related Cancer
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Other
Companies covered
  • Takeda
  • Johnson & Johnson
  • Novartis
  • Merck KGaA
  • Roche
  • Eli Lilly
  • Pfizer
  • GSK
  • Amgen
  • AbbVie
  • AstraZeneca
  • Seagen
  • Regeneron
  • Ono Pharmaceutical
  • Merck & Co
  • Innovent
  • Hengrui Medicine
  • Gilead Sciences
  • Exelixis
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cancer Immunotherapy Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Cancer Immunotherapy Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Cancer Immunotherapy Drugs Market by Type
  6. 1.3.1 CAR-T Cell Therapy
  7. 1.3.2 Cytokine-Based Immunotherapy
  8. 1.3.3 Immune Checkpoint Inhibitors
  9. 1.3.4 Other
  10. 1.4 Global Cancer Immunotherapy Drugs Market Size by Type
  11. 1.4.1 Global Cancer Immunotherapy Drugs Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Cancer Immunotherapy Drugs Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Cancer Immunotherapy Drugs Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Cancer Immunotherapy Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Cancer Immunotherapy Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Cancer Immunotherapy Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Cancer Immunotherapy Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Cancer Immunotherapy Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Cancer Immunotherapy Drugs Industry Trends
  2. 2.2 Cancer Immunotherapy Drugs Industry Drivers
  3. 2.3 Cancer Immunotherapy Drugs Industry Opportunities and Challenges
  4. 2.4 Cancer Immunotherapy Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Cancer Immunotherapy Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Cancer Immunotherapy Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Cancer Immunotherapy Drugs Price (2021-2026)
  4. 3.4 Global Cancer Immunotherapy Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Immunotherapy Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Cancer Immunotherapy Drugs Company, Product Type & Application
  7. 3.7 Global Cancer Immunotherapy Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Immunotherapy Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Immunotherapy Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Immunotherapy Drugs Tier 1, Tier 2, and Tier 3
4 Cancer Immunotherapy Drugs Regional Status and Outlook
  1. 4.1 Global Cancer Immunotherapy Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Cancer Immunotherapy Drugs Historic Market Size by Region
  3. 4.2.1 Global Cancer Immunotherapy Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Cancer Immunotherapy Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Cancer Immunotherapy Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Cancer Immunotherapy Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Cancer Immunotherapy Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Cancer Immunotherapy Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Cancer Immunotherapy Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Cancer Immunotherapy Drugs by Application
  1. 5.1 Cancer Immunotherapy Drugs Market by Application
  2. 5.1.1 Blood-related Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Prostate Cancer
  5. 5.1.4 Lung Cancer
  6. 5.1.5 Other
  7. 5.2 Global Cancer Immunotherapy Drugs Market Size by Application
  8. 5.2.1 Global Cancer Immunotherapy Drugs Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Cancer Immunotherapy Drugs Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Cancer Immunotherapy Drugs Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Cancer Immunotherapy Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Cancer Immunotherapy Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Cancer Immunotherapy Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Cancer Immunotherapy Drugs Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Cancer Immunotherapy Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Takeda
  2. 6.1.1 Takeda Company Information
  3. 6.1.2 Takeda Business Overview
  4. 6.1.3 Takeda Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Cancer Immunotherapy Drugs Product Portfolio
  6. 6.1.5 Takeda Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Johnson & Johnson Cancer Immunotherapy Drugs Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Novartis Cancer Immunotherapy Drugs Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Merck KGaA
  20. 6.4.1 Merck KGaA Company Information
  21. 6.4.2 Merck KGaA Business Overview
  22. 6.4.3 Merck KGaA Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Merck KGaA Cancer Immunotherapy Drugs Product Portfolio
  24. 6.4.5 Merck KGaA Recent Developments
  25. 6.5 Roche
  26. 6.5.1 Roche Company Information
  27. 6.5.2 Roche Business Overview
  28. 6.5.3 Roche Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Roche Cancer Immunotherapy Drugs Product Portfolio
  30. 6.5.5 Roche Recent Developments
  31. 6.6 Eli Lilly
  32. 6.6.1 Eli Lilly Company Information
  33. 6.6.2 Eli Lilly Business Overview
  34. 6.6.3 Eli Lilly Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Eli Lilly Cancer Immunotherapy Drugs Product Portfolio
  36. 6.6.5 Eli Lilly Recent Developments
  37. 6.7 Pfizer
  38. 6.7.1 Pfizer Company Information
  39. 6.7.2 Pfizer Business Overview
  40. 6.7.3 Pfizer Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Pfizer Cancer Immunotherapy Drugs Product Portfolio
  42. 6.7.5 Pfizer Recent Developments
  43. 6.8 GSK
  44. 6.8.1 GSK Company Information
  45. 6.8.2 GSK Business Overview
  46. 6.8.3 GSK Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 GSK Cancer Immunotherapy Drugs Product Portfolio
  48. 6.8.5 GSK Recent Developments
  49. 6.9 Amgen
  50. 6.9.1 Amgen Company Information
  51. 6.9.2 Amgen Business Overview
  52. 6.9.3 Amgen Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Amgen Cancer Immunotherapy Drugs Product Portfolio
  54. 6.9.5 Amgen Recent Developments
  55. 6.10 AbbVie
  56. 6.10.1 AbbVie Company Information
  57. 6.10.2 AbbVie Business Overview
  58. 6.10.3 AbbVie Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 AbbVie Cancer Immunotherapy Drugs Product Portfolio
  60. 6.10.5 AbbVie Recent Developments
  61. 6.11 AstraZeneca
  62. 6.11.1 AstraZeneca Company Information
  63. 6.11.2 AstraZeneca Business Overview
  64. 6.11.3 AstraZeneca Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 AstraZeneca Cancer Immunotherapy Drugs Product Portfolio
  66. 6.11.5 AstraZeneca Recent Developments
  67. 6.12 Seagen
  68. 6.12.1 Seagen Company Information
  69. 6.12.2 Seagen Business Overview
  70. 6.12.3 Seagen Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Seagen Cancer Immunotherapy Drugs Product Portfolio
  72. 6.12.5 Seagen Recent Developments
  73. 6.13 Regeneron
  74. 6.13.1 Regeneron Company Information
  75. 6.13.2 Regeneron Business Overview
  76. 6.13.3 Regeneron Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Regeneron Cancer Immunotherapy Drugs Product Portfolio
  78. 6.13.5 Regeneron Recent Developments
  79. 6.14 Ono Pharmaceutical
  80. 6.14.1 Ono Pharmaceutical Company Information
  81. 6.14.2 Ono Pharmaceutical Business Overview
  82. 6.14.3 Ono Pharmaceutical Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Ono Pharmaceutical Cancer Immunotherapy Drugs Product Portfolio
  84. 6.14.5 Ono Pharmaceutical Recent Developments
  85. 6.15 Merck & Co
  86. 6.15.1 Merck & Co Company Information
  87. 6.15.2 Merck & Co Business Overview
  88. 6.15.3 Merck & Co Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Merck & Co Cancer Immunotherapy Drugs Product Portfolio
  90. 6.15.5 Merck & Co Recent Developments
  91. 6.16 Innovent
  92. 6.16.1 Innovent Company Information
  93. 6.16.2 Innovent Business Overview
  94. 6.16.3 Innovent Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Innovent Cancer Immunotherapy Drugs Product Portfolio
  96. 6.16.5 Innovent Recent Developments
  97. 6.17 Hengrui Medicine
  98. 6.17.1 Hengrui Medicine Company Information
  99. 6.17.2 Hengrui Medicine Business Overview
  100. 6.17.3 Hengrui Medicine Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Hengrui Medicine Cancer Immunotherapy Drugs Product Portfolio
  102. 6.17.5 Hengrui Medicine Recent Developments
  103. 6.18 Gilead Sciences
  104. 6.18.1 Gilead Sciences Company Information
  105. 6.18.2 Gilead Sciences Business Overview
  106. 6.18.3 Gilead Sciences Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Gilead Sciences Cancer Immunotherapy Drugs Product Portfolio
  108. 6.18.5 Gilead Sciences Recent Developments
  109. 6.19 Exelixis
  110. 6.19.1 Exelixis Company Information
  111. 6.19.2 Exelixis Business Overview
  112. 6.19.3 Exelixis Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Exelixis Cancer Immunotherapy Drugs Product Portfolio
  114. 6.19.5 Exelixis Recent Developments
  115. 6.20 Bristol-Myers Squibb
  116. 6.20.1 Bristol-Myers Squibb Company Information
  117. 6.20.2 Bristol-Myers Squibb Business Overview
  118. 6.20.3 Bristol-Myers Squibb Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Bristol-Myers Squibb Cancer Immunotherapy Drugs Product Portfolio
  120. 6.20.5 Bristol-Myers Squibb Recent Developments
7 North America by Country
  1. 7.1 North America Cancer Immunotherapy Drugs Sales by Country
  2. 7.1.1 North America Cancer Immunotherapy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Cancer Immunotherapy Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Cancer Immunotherapy Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Cancer Immunotherapy Drugs Market Size by Country
  6. 7.2.1 North America Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Cancer Immunotherapy Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Cancer Immunotherapy Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Cancer Immunotherapy Drugs Sales by Country
  2. 8.1.1 Europe Cancer Immunotherapy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Cancer Immunotherapy Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Cancer Immunotherapy Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Cancer Immunotherapy Drugs Market Size by Country
  6. 8.2.1 Europe Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Cancer Immunotherapy Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Cancer Immunotherapy Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Cancer Immunotherapy Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Cancer Immunotherapy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Cancer Immunotherapy Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Cancer Immunotherapy Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Cancer Immunotherapy Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Cancer Immunotherapy Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Cancer Immunotherapy Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Cancer Immunotherapy Drugs Sales by Country
  2. 10.1.1 South America Cancer Immunotherapy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Cancer Immunotherapy Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Cancer Immunotherapy Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Cancer Immunotherapy Drugs Market Size by Country
  6. 10.2.1 South America Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Cancer Immunotherapy Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Cancer Immunotherapy Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Cancer Immunotherapy Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Cancer Immunotherapy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Cancer Immunotherapy Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Cancer Immunotherapy Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Cancer Immunotherapy Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Cancer Immunotherapy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Cancer Immunotherapy Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Cancer Immunotherapy Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Cancer Immunotherapy Drugs Value Chain Analysis
  2. 12.1.1 Cancer Immunotherapy Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Cancer Immunotherapy Drugs Production Mode & Process
  7. 12.2 Cancer Immunotherapy Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Cancer Immunotherapy Drugs Distributors
  10. 12.2.3 Cancer Immunotherapy Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst